Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway
Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. I...
Gespeichert in:
Veröffentlicht in: | Experimental and therapeutic medicine 2017-10, Vol.14 (4), p.2853-2862 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2862 |
---|---|
container_issue | 4 |
container_start_page | 2853 |
container_title | Experimental and therapeutic medicine |
container_volume | 14 |
creator | Ma, Wei Kang, Yanhong Ning, Lanlan Tan, Jie Wang, Hanping Ying, Yi |
description | Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EG |
doi_str_mv | 10.3892/etm.2017.4847 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5585727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979111433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</originalsourceid><addsrcrecordid>eNpdkU1rFTEUhoMottQu3UrAjZu5JpmPJBuhFG0LRUF0HTL5mEnNJNckc0v_jL_VDL0WNZtzyHnykvO-ALzGaNcyTt6bsuwIwnTXsY4-A6eYctJghPvnxx5xhk_Aec53qJ5-wIz1L8EJYRyT-uQU_LrRJhRnnZLFxQCjhYtTKX79fJGhC4foD0bXBk7GuuKCG2Ey2eUigzIbHWJo8iK9b5TxHvo1TFBtwwTLnOI6zbWaqpBX70Lj3Q8DpxTvywytVCWmqqfMfmswzG4KsmIT3Msy38uHV-CFlT6b82M9A98_ffx2ed3cfrm6uby4bVSH-9Joq1vWEk3w2JGW9pYOAyPM4GEcEOHbrdZ6YIZI3lHGkbWDkVpLPg54VKo9Ax8edffruBitqidJerFPbpHpQUTpxL-T4GYxxYPoe9ZTQqvAu6NAij9Xk4tYXN4ckcHENQvMu-o_Yi2q6Nv_0Lu4prr3RlGOMe7atlLNI1XDyDkZ-_QZjMQWvqjhiy18sYVf-Td_b_BE_4m6_Q3dFa7k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979111433</pqid></control><display><type>article</type><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><source>PubMed Central</source><creator>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</creator><creatorcontrib>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</creatorcontrib><description>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2017.4847</identifier><identifier>PMID: 28912847</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Drug resistance ; Epidermal growth factor ; Inhibitor drugs ; Insulin-like growth factors ; Kinases ; Lung cancer ; Metastasis ; MicroRNAs ; Mutation ; Proteins ; Studies ; Targeted cancer therapy ; Tumors</subject><ispartof>Experimental and therapeutic medicine, 2017-10, Vol.14 (4), p.2853-2862</ispartof><rights>Copyright Spandidos Publications UK Ltd. 2017</rights><rights>Copyright: © Ma et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</citedby><cites>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585727/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585727/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28912847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Kang, Yanhong</creatorcontrib><creatorcontrib>Ning, Lanlan</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Hanping</creatorcontrib><creatorcontrib>Ying, Yi</creatorcontrib><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</description><subject>Drug resistance</subject><subject>Epidermal growth factor</subject><subject>Inhibitor drugs</subject><subject>Insulin-like growth factors</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Metastasis</subject><subject>MicroRNAs</subject><subject>Mutation</subject><subject>Proteins</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkU1rFTEUhoMottQu3UrAjZu5JpmPJBuhFG0LRUF0HTL5mEnNJNckc0v_jL_VDL0WNZtzyHnykvO-ALzGaNcyTt6bsuwIwnTXsY4-A6eYctJghPvnxx5xhk_Aec53qJ5-wIz1L8EJYRyT-uQU_LrRJhRnnZLFxQCjhYtTKX79fJGhC4foD0bXBk7GuuKCG2Ey2eUigzIbHWJo8iK9b5TxHvo1TFBtwwTLnOI6zbWaqpBX70Lj3Q8DpxTvywytVCWmqqfMfmswzG4KsmIT3Msy38uHV-CFlT6b82M9A98_ffx2ed3cfrm6uby4bVSH-9Joq1vWEk3w2JGW9pYOAyPM4GEcEOHbrdZ6YIZI3lHGkbWDkVpLPg54VKo9Ax8edffruBitqidJerFPbpHpQUTpxL-T4GYxxYPoe9ZTQqvAu6NAij9Xk4tYXN4ckcHENQvMu-o_Yi2q6Nv_0Lu4prr3RlGOMe7atlLNI1XDyDkZ-_QZjMQWvqjhiy18sYVf-Td_b_BE_4m6_Q3dFa7k</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Ma, Wei</creator><creator>Kang, Yanhong</creator><creator>Ning, Lanlan</creator><creator>Tan, Jie</creator><creator>Wang, Hanping</creator><creator>Ying, Yi</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><author>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Drug resistance</topic><topic>Epidermal growth factor</topic><topic>Inhibitor drugs</topic><topic>Insulin-like growth factors</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Metastasis</topic><topic>MicroRNAs</topic><topic>Mutation</topic><topic>Proteins</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Kang, Yanhong</creatorcontrib><creatorcontrib>Ning, Lanlan</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Hanping</creatorcontrib><creatorcontrib>Ying, Yi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Wei</au><au>Kang, Yanhong</au><au>Ning, Lanlan</au><au>Tan, Jie</au><au>Wang, Hanping</au><au>Ying, Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>14</volume><issue>4</issue><spage>2853</spage><epage>2862</epage><pages>2853-2862</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>28912847</pmid><doi>10.3892/etm.2017.4847</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1792-0981 |
ispartof | Experimental and therapeutic medicine, 2017-10, Vol.14 (4), p.2853-2862 |
issn | 1792-0981 1792-1015 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5585727 |
source | PubMed Central |
subjects | Drug resistance Epidermal growth factor Inhibitor drugs Insulin-like growth factors Kinases Lung cancer Metastasis MicroRNAs Mutation Proteins Studies Targeted cancer therapy Tumors |
title | Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A29%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20microRNAs%20involved%20in%20gefitinib%20resistance%20of%20non-small-cell%20lung%20cancer%20through%20the%20insulin-like%20growth%20factor%20receptor%201%20signaling%20pathway&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Ma,%20Wei&rft.date=2017-10-01&rft.volume=14&rft.issue=4&rft.spage=2853&rft.epage=2862&rft.pages=2853-2862&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2017.4847&rft_dat=%3Cproquest_pubme%3E1979111433%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979111433&rft_id=info:pmid/28912847&rfr_iscdi=true |